Current progress of siRNA/shRNA therapeutics in clinical trials

Biotechnol J. 2011 Sep;6(9):1130-46. doi: 10.1002/biot.201100054. Epub 2011 Jul 11.


Through a mechanism known as RNA interference (RNAi), small interfering RNA (siRNA) molecules can target complementary mRNA strands for degradation, thus specifically inhibiting gene expression. The ability of siRNAs to inhibit gene expression offers a mechanism that can be exploited for novel therapeutics. Indeed, over the past decade, at least 21 siRNA therapeutics have been developed for more than a dozen diseases, including various cancers, viruses, and genetic disorders. Like other biological drugs, RNAi-based therapeutics often require a delivery vehicle to transport them to the targeted cells. Thus, the clinical advancement of numerous siRNA drugs has relied on the development of siRNA carriers, including biodegradable nanoparticles, lipids, bacteria, and attenuated viruses. Most therapies permit systemic delivery of the siRNA drug, while others use ex vivo delivery by autologous cell therapy. Advancements in bioengineering and nanotechnology have led to improved control of delivery and release of some siRNA therapeutics. Likewise, progress in molecular biology has allowed for improved design of the siRNA molecules. Here, we provide an overview of siRNA therapeutics in clinical trials, including their clinical progress, the challenges they have encountered, and the future they hold in the treatment of human diseases.

Publication types

  • Review

MeSH terms

  • Animals
  • Cell- and Tissue-Based Therapy
  • Clinical Trials as Topic
  • Humans
  • RNA Interference / physiology
  • RNA, Small Interfering / genetics
  • RNA, Small Interfering / physiology*


  • RNA, Small Interfering